Last updated: May 26, 2026
Qutenza (capsaicin) 8% topical system is supplied in the U.S. market by Aquestive Therapeutics (brand holder) and manufactured for the label by Hovione (capsaicin and patch manufacturing supply chain).
Because Qutenza is distributed as a finished dosage form and requires tightly controlled manufacturing for the drug-in-adhesive patch, the supplier picture is typically split into (1) finished-device/patch manufacturing and (2) upstream API and excipient inputs.
Who supplies Qutenza in the U.S. and who manufactures the product?
Primary market supply chain (finished product):
- Marketing authorization holder / U.S. distributor (brand): Aquestive Therapeutics, Inc.
- Manufacturing / finished dosage supply (patch): Hovione (capsaicin 8% medicated plaster/patch manufacturing supplier for Qutenza)
This division matches how FDA labeling and standard supply arrangements typically map: the brand holder controls U.S. commercialization while an external CMO supplies finished Qutenza.
What is the manufacturing scope for a capsaicin 8% patch supplier?
For Qutenza-type systems, patch suppliers must control:
- Capsaicin distribution in the adhesive matrix
- Patch thickness, tack, adhesion time, and backing material performance
- Microbial and residual solvent controls aligned to topical GMP
- Packaging that preserves potency and prevents moisture/handling variability
What upstream suppliers provide capsaicin API and excipients used in Qutenza?
Capsaicin (API) and key excipients are commonly sourced from specialist fine-chemical suppliers and adhesive excipient manufacturers, but Qutenza sourcing is generally managed through Hovione’s controlled supplier network and qualification systems.
For patch products, the upstream inputs that typically require dedicated vendor control include:
- Capsaicin (raw material consistency, impurity profile)
- Adhesive polymer system used to bind drug to skin
- Backing material that defines occlusivity and comfort
- Release liner used during patch removal and application
Qutenza’s published supplier list at the API/excipient vendor level is not typically disclosed in public FDA label documents the way finished-manufacturing and sponsor names are. The practical way the market treats this is that the CMO (Hovione) and brand holder (Aquestive) own vendor qualification and incoming QC acceptance.
What is the patent and regulatory footprint that affects who can supply Qutenza?
Qutenza remains a branded, reference-listed product with exclusivity and patent constraints on generic patch supply. This affects who can compete with supply, not only the manufacturing of the brand itself.
What is Qutenza’s FDA status that shapes supplier entry risk?
Qutenza is regulated as an NDA topical drug (capsaicin 8% patch system). The core supplier constraints come from:
- Orange Book listings for formulation and method-of-use claims tied to the patch system
- NDA manufacturing controls and stability requirements for topical patches
- Packaging and handling restrictions used in the REMS-free but highly controlled topical setting
How do supply contracts typically work for Qutenza-style patch products?
In patch systems, commercial supply typically uses one or more of the following structures:
- Single-source CMO for finished patch (most common for complex adhesive matrix systems)
- Dual-source backup manufacturing to manage capacity and quality deviations
- In-house release at the CMO site with batch release performed under QA systems aligned to the NDA
For Qutenza, the market-facing manufacturing supplier is Hovione, with Aquestive handling U.S. market distribution and brand-side quality agreements.
Which companies are relevant to Qutenza supply beyond the brand holder and CMO?
Beyond the marketing/distribution and finished manufacturing entities, the relevant industrial roles are:
- Labeler/distributor: Aquestive Therapeutics
- Finished patch manufacturing CMO: Hovione
- Downstream logistics and wholesalers: U.S. distribution network (pharmacy channels)
- Clinical administration supply chain: patch kits and application workflow (healthcare provider ordering)
- Regulated packaging suppliers: primary packaging that preserves patch integrity and labeling compliance
Publicly identifiable, vendor-level names for packaging components and excipient suppliers are usually controlled through NDA manufacturing agreements and do not surface as a standalone “supplier list” in FDA-facing documents.
Key takeaways
- U.S. Qutenza supply is led by Aquestive Therapeutics as the brand holder/distributor.
- Finished Qutenza patch manufacturing is supplied by Hovione.
- Upstream API and excipient sourcing is controlled through CMO qualification networks, with the market typically treating Hovione as the accountable supply chain for the drug-in-adhesive system.
FAQs
1) Who makes Qutenza patches (capsaicin 8%)?
Hovione is the identified patch manufacturing supplier for Qutenza’s finished dosage.
2) Who distributes Qutenza in the United States?
Aquestive Therapeutics is the U.S. brand/distributor.
3) Can suppliers introduce a “generic Qutenza patch” by buying capsaicin and adhesive?
No. A legal generic/ANDA (or other pathway) depends on FDA review, Orange Book freedom-to-operate, and patch-specific manufacturing and quality controls.
4) Are there multiple manufacturing sites for Qutenza?
Qutenza supply is typically structured around an external CMO manufacturing network; the market reference point for finished patch supply is Hovione.
5) What upstream inputs are most critical for capsaicin patch manufacturing?
Capsaicin API, adhesive polymer system, backing material, and release liner integrity under NDA-aligned specifications.
References (APA)
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. (Orange Book database entry for Qutenza).
- FDA. Drugs@FDA: Qutenza (capsaicin) topical system. U.S. Food and Drug Administration.
- Labeling/Drug product information for Qutenza (capsaicin 8% patch system). FDA-approved prescribing information.
